Eli Lilly has won FDA approval for a once-weekly insulin shot, a significant milestone in diabetes care. The approval, reported by STAT, introduces the first weekly insulin option, potentially reducing the burden of daily injections for millions of patients. This could improve adherence and quality of life, though the source does not specify the drug's brand name or clinical trial outcomes.
The approval arrives alongside other biotech news in the same report, including a jury verdict against Lilly. A California federal jury found that Lilly breached a contract with Nektar Therapeutics to co-develop the autoimmune drug rezpeg, awarding Nektar $90 million in damages—far less than sought. The source does not indicate whether this legal outcome is related to the insulin approval.
While the source highlights the approval as a headline event, it lacks details on pricing, availability, or comparative effectiveness against daily insulins. The report also notes broader industry activity, such as City Therapeutics' IPO filing and FDA nominee hearings, but these are unrelated to the insulin news. Overall, the approval represents a notable advance, though further information is needed to assess its full impact.